Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis in Africa
NCT06213506Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GVGH iNTS GMMA vaccine in salmonellosis, sponsored by GSK. Started Jan 2024; status: completed.
02
Drugs
GVGH iNTS GMMA vaccine
03
Conditions
salmonellosis
Beyond the preview
Go deeper on NCT06213506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213506.